Shots:

• AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) utilizing artificial intelligence (AI) and machine learning
• AstraZeneca will combine its genomics- chemistry and clinical data with Benevolent AI’s target identification platform and biomedical knowledge graph (network of genes- proteins- diseases and compounds) and will have insights of CKD and IPF diseases for identifying targets
• Benevolent AI platform is a computational & experimental drug discovery platform which allows findings of pathways to treat disease and personalize drugs to patients focusing on four key areas: knowledge & reasoning- target identification- molecular design and precision medicine

Ref: AstraZeneca | Image: AstraZeneca